Trump announces drug pricing deals with nine more manufacturers
President Donald Trump announced agreements wiht nine additional major drug manufacturers under his “most favored nation” (MFN) drug pricing initiative. This brings the total number of deals to 14 out of the 17 largest global pharmaceutical companies. The new agreements include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi, joining previously announced deals with AstraZeneca, Eli Lilly, EMD Serono, novo Nordisk, and Pfizer.
Trump credited the threat of tariffs as a key factor motivating pharmaceutical companies to accept lower drug prices. The agreements aim to reduce drug costs significantly starting next year, making U.S. drug prices some of the lowest among developed countries. These deals notably impact medicaid drug prices, with protections for vulnerable citizens and a mechanism to recoup savings when foreign prices are higher.
Health and Human Services Secretary Robert F. kennedy Jr. praised the initiative as a historic achievement in making drugs more affordable, a goal long sought by political figures across party lines. The management states that many drug prices covered by Medicaid are currently higher than in other countries,and the MFN agreements will result in immediate relief for beneficiaries.
While Medicare and consumer insurance plan holders may not see immediate reductions, thay can buy certain drugs directly at MFN prices through Trump’s new website, TrumpRx.com. Administration officials noted a rapid shift from initial industry hesitation to widespread cooperation, describing the growing adoption of MFN agreements as moving quickly from a bold policy to an industry standard.
Trump described the initiative as the biggest breakthrough in healthcare affordability in American history and thanked the pharmaceutical executives for their cooperation at the announcement event.
Trump announces deals with nine more drug manufacturers
President Donald Trump unveiled “most favored nation” drug agreements with nine manufacturers on Friday, with senior administration officials claiming that pharmaceutical companies are now rushing to ink deals of their own with the president.
In total, Trump has signed deals with 14 of the world’s 17 largest drug manufacturers. Friday’s newly announced agreements were with Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi, on top of previous announcements of deals with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
Trump’s predecessor, former President Joe Biden, similarly sought to negotiate with drug manufacturers on domestic prices but saw little success. Trump credited his tariff slate with bringing the pharmaceutical executives to the table.
“We told them, ‘If you don’t do it, we’re going to have to use tariffs, and we’re going to charge you a 10% tariff,’ which is far more money than the money we’re talking about,” the president said at the White House. “And they immediately agreed to do it. They said, ‘Is it a threat?’ I said, ‘Yes, it is a threat,’ and they said, ‘We will do it,’ and they dropped the price.
“Starting next year, American drug prices will come down fast and furious and will soon be among the lowest in the developed world,” he continued.
Robert F. Kennedy, Jr., Trump’s Secretary of Health and Human Services, lauded the president during Friday’s event for succeeding where top Democratic lawmakers have failed for years.
“This is the best achievement that could happen to our country. This is something Bernie Sanders has been clamoring for for 25 years, Elizabeth Warren has been clamoring for, Joe Biden promised the American people, President Obama, President Clinton, all promised to do this for the American people,” Kennedy claimed. “You talk about affordability. People are talking about affordability. Nobody has done anything for affordability greater than this.”
Senior administration officials confirmed Friday morning that the new deals are structured the same as the president’s previous deals.
“The majority of each Medicaid portfolio will be priced at MFN effective nearly immediately, protecting our most vulnerable citizens on Medicaid,” one official explained, adding that the deals also feature the same “shared savings mechanism” as before. “When foreign countries pay more for existing drugs, a portion of that revenue will be remitted back to the United States to offset costs so that Americans pay less.”
Trump administration officials claim that roughly 30%-40% of drugs within the Medicaid umbrella are priced higher than in overseas markets and that program beneficiaries will see near immediate price relief.
People on Medicare or consumer insurance plans will similarly be able to purchase new-to-market drugs at MFN prices in the future, but they likely will not see an immediate decrease in their prescription costs. Administration officials noted that those people can also purchase drugs out of pocket, at MFN prices, on TrumpRx.com, the president’s new website aimed at providing people with affordable, direct-to-consumer options to shop for pharmaceuticals.
“This is no longer a trickle,” one senior administration official said ahead of the president’s announcement. “This is a flood. In a sense, it’s gone from a bold policy to an industry standard, and it’s happened in record time. Our phones are ringing off the hook. Our inboxes are overflowing with additional pharmaceutical companies that are seeking to sign MFN agreements with the United States government. What we’ve observed is initial industry hesitance collapsing into cooperation.”
Trump was joined at his announcement ceremony by executives from the nine pharmaceutical companies, whom the president thanked for delivering “the greatest victory for patient affordability in the history of American healthcare.”
“Every single American will benefit,” Trump said. “This is the biggest thing ever to happen on drug pricing and on healthcare, and this will have a tremendous impact on healthcare itself. People used to talk about this for years, but nobody ever did anything about it. No other president did, and it wasn’t easy, but it worked out great.”
Trump’s comments can be seen in full below.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
